

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 March 2002 (14.03.2002)

PCT

(10) International Publication Number
WO 02/20523 A1(51) International Patent Classification⁷: C07D 471/04,
213/803, 213/82

(21) International Application Number: PCT/SE01/01897

(22) International Filing Date:
5 September 2001 (05.09.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0003186-4 7 September 2000 (07.09.2000) SE(71) Applicant (for all designated States except US): AS-
TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ELMAN, Björn
[SE/SE]; Skolgatan 22, S-195 34 Märsta (SE). ERBACK,
Silke [DE/CH]; Kirchgasse 6B, CH-5742 Kolliken (CH).
THIEMERMANN, Eric [DE/CH]; Route de L'Aurore
2D, CH-1700 Fribourg (CH).(74) Agent: ASTRAZENECA AB; Global Intellectual Prop-
erty, S-151 85 Södertälje (SE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND

(57) Abstract: The present invention provides a new process for large-scale preparation of substituted imidazopyridine compound of formula (I) wherein R¹ is C₁-C₆ alkoxy or NH₂ group, comprising the step of reacting a compound of formula (2) with a 3-halo-2-butanone compound in cyclohexanone.

WO 02/20523 A1


PROCESS FOR PREPARING A SUBSTITUTED IMIDAZOPYRIDINE COMPOUND

FIELD OF THE INVENTION

The present invention relates to a new process for the preparation of a substituted
5 imidazopyridine compound, more specifically a new process for the preparation of a 2,3-
dimethylimidazo[1,2-a]pyridine substituted in the 6-position by a carboxamido or a
carboxyalkyl group. In further aspects, the present invention also relates to new
intermediates used in the process.

10 BACKGROUND AND PRIOR ART


The present invention relates to a new process suitable for large-scale preparation of a
substituted imidazopyridine compound of formula (1),



(1)

15

wherein R^1 is a C_1 - C_6 alkoxy or NH_2 group, comprising the step of reacting a compound
of the formula (2)




(2)

20 wherein R^1 is a C_1 - C_6 alkoxy or NH_2 group, with a 3-halo-2-butanone compound in
cyclohexanone.


2

A similar reaction is described in EP 33094, EP 204 285, EP 228 006, EP 308 917, and WO 99/55706 wherein a substituted aminopyridine compound of the general formula (X)



(X)


5



wherein X is i.a. H , CH_3 or an ester group, such as COOCH_3 or COOC_2H_5 ,

Y is i.a. CH_3 , CH_2CH_3 , and

10 Z is a leaving group, such as halogen, mesyl or tosyl,
to give a compound of the general structure



15 wherein X and Y are as described above.

The reaction is carried out in an inert solvent, such as acetone, alcohols, benzene, N,N -dimethylformamide, tetrahydrofuran, chloroform, or diethyl ether, preferably at elevated temperature, and optionally in the presence of an inorganic or organic base.


20

The reaction is characterized by long reaction times, *e.g.* 16 to 84 hours, high reaction temperatures and relatively low yields, *e.g.* 22% to 55%. The reaction is thereby not suitable for large-scale preparation of substituted imidazopyridine compounds.

- 5 We have surprisingly found that if the process of the present invention is carried out as described herein the reaction time can be shortened, the reaction temperature can be lowered and the yield is increased.


OUTLINE OF THE INVENTION

- 10 The present invention provides a new process for large-scale preparation of substituted imidazopyridine compound of formula (1)



(1)

- 15 wherein R¹ is a C₁-C₆ alkoxy or NH₂ group, comprising the step of reacting a compound of the formula (2)




(2)

with a 3-halo-2-butanone compound in cyclohexanone.


In a first embodiment of the present invention a compound of the formula (2)

4



(2)


wherein R^1 is a C_1 - C_6 alkoxy group, is reacted with a 3-halo-2-butanone compound in cyclohexanone to give a compound of the formula (1)



(1)

wherein R^1 is a C_1 - C_6 alkoxy group.


In a second embodiment of the present invention a compound of the formula (2)



(2)

wherein R^1 is a NH_2 group, is reacted with a 3-halo-2-butanone compound in cyclohexanone to give a compound of the formula (1)


5



(1)


wherein R^1 is NH_2 group.

- 5 The process of the present invention is performed by solving or suspending a compound of formula (2)



(2)

- wherein R^1 is a C_1 - C_6 alkoxy or NH_2 group, in cyclohexanone and adding a 3-halo-2-butanone compound, heat the reaction for a few hours and thereafter isolate a compound of formula (1)
- 10



(1)


- 15 wherein R^1 is a C_1 - C_6 alkoxy or NH_2 group, in high yields.

The amount of cyclohexanone is not crucial for carrying out the present invention, and can therefore in practical circumstances be adjusted according to needs and equipment used. It is also possible to mix cyclohexanone with inert solvents, such as ethers. Example of suitable inert solvents comprises, but is not limited, to tetrahydrofuran (THF). The amount of inert solvent can be up to around 50%, by volume, without causing a decrease in yield.

The amount of 3-halo-2-butanone compound is not critical for carrying out the present invention. It is for practical and economical reasons preferred to add 1.1 to 5 molar equivalents, preferably 1.1 to 2 equivalents. Example of suitable 3-halo-2-butanone compounds comprises, but is not limited, 3-bromo-2-butanone and 3-chloro-2-butanone, of which the latter is preferred.

Reaction temperatures and reaction times can be varied to meet the actual need. It is preferred to have a reaction temperature from 80°C to 100°C. This reaction temperature gives a complete reaction within a few hours, e.g. 1 to 4 hours. Conversion is usually above 95% and the isolated yield is usually above 70%.

The starting material to be used in the present invention can be prepared as disclosed in WO 99/55706 or alternatively as is described below in Scheme 1.



Scheme 1

Step i

Compound (3) in Scheme 1 is treated with thionyl chloride, or any equivalent reagent, at elevated temperature in an appropriate solvent for a few hours to give the corresponding chloride compound. The reaction is performed using around 1 to 5 equivalents thionyl

chloride, preferably 1 to 2.5 equivalents, in toluene at approximately 100°C for 2 to 8 hours. The corresponding chloride compound is thereafter treated with 2 to 25 equivalents ammonia, preferably 3 to 12 equivalents, in the same solvent as above at approximately ambient temperature to give compound (4).

Step ii

Compound (4) in Scheme 1 is hydrogenated in an aqueous alcoholic solution using a catalyst to give compound (5). Example of suitable catalyst comprises, but is not limited, to palladium, ruthenium or mixtures thereof. Pd-Ru/C paste is the preferred catalyst.

Examples of alcohols comprises, but is not limited to, methanol, ethanol and propanol, of which methanol is preferred.

The substituted imidazopyridine compound of formula (1),




(1)

wherein R^1 is a C_1 - C_6 alkoxy or NH_2 group, prepared according to the present invention can thereafter be used to prepare certain substituted imidazopyridine derivatives that are particularly effective as inhibitors of the gastrointestinal H^+ , K^+ -ATPase and thereby as inhibitors of gastric acid secretion.


Compounds of the Formula (1) can be reacted with a compound of the Formula (6)

8



(6)

wherein R^3 is H, C_1 - C_6 alkyl, hydroxylated C_1 - C_6 alkyl or halogen; R^4 is H, C_1 - C_6 alkyl, hydroxylated C_1 - C_6 alkyl or halogen; R^5 is H, or halogen; and Y is a leaving group, such as a halide, tosyl or mesyl group, to give a compound of Formula (7).




(7)

wherein R^1 , R^3 , R^4 , and R^5 are as defined above. It is convenient to conduct this reaction in an inert solvent, e.g. acetone, acetonitrile, dimethoxyethane, methanol, ethanol or dimethylformamide with or without a base. The base is e.g. an alkali metal hydroxide, such as sodium hydroxide and potassium hydroxide, an alkali metal carbonate, such as potassium carbonate and sodium carbonate; or an organic amine, such as triethylamine.

Compounds of the Formula (7) wherein R^1 is C_1 - C_6 alkoxy can thereafter be further reacted with an amino compound of the general Formula (8)

9



(8)

wherein R^6 and R^7 are the same or different and chosen from a group consisting of H, C_1 - C_6 alkyl, hydroxylated C_1 - C_6 alkyl, C_1 - C_6 alkoxy-substituted C_1 - C_6 alkyl, hydroxylated
 5 C_1 - C_6 alkoxy-substituted C_1 - C_6 alkyl, aryl, to give the corresponding amide compound.


R^6 and R^7 may together with the nitrogen atom to which they are attached, form a saturated or unsaturated ring optionally containing one or more further heteroatoms thereby forming e.g. morpholine, piperazine, pyrrolidine, or piperidine.

10

The reaction can be carried out by heating the reactants in the neat amino compound or dissolved in an inert solvent under standard conditions.

Alternatively can compounds of the Formula (7)

15




(7)

wherein R^3 , R^4 , and R^5 are as defined above and R^1 is an NH_2 group, be hydrolyzed under standard conditions to the corresponding carboxylic acid compounds of Formula (9)

20


10



(9)

wherein R³, R⁴, and R⁵ are as defined above.

- 5 Compounds of the Formula (9) can thereafter be reacted with amino compounds of Formula (8)



(8)


- 10 wherein R⁶ and R⁷ are as defined above, in the presence of a coupling reagent to give the corresponding amide compound. The reaction can be carried out in an inert solvent under standard conditions.

EXAMPLES

15 *Example 1.1*

Preparation of Bromobutanone


- In a reactor, sodium bromide (84 kg) is suspended in dimethylformamide (125 l). 3-Chloro-2-butanone (85 kg) is added at 15°C-30°C. Stirring is continued for 4 hours and then filtered: The filtercake is washed with cyclohexanone (38 l). The bromobutanone
20 thereby prepared is ready to be used in the cyclisation step.

*Example 1.2**Synthesis of methyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate*

5

To a suspension of 5,6-diamino-nicotinic acid methyl ester (1 eq., 5.1 g) in cyclohexanone (50 ml) bromobutanone (1.2 equiv., 3.9 ml) was added over 10 min. The mixture was heated to 100°C (inner temperature) and stirred 2.5 h at this temperature. The mixture was cooled to room temperature and the pale solid was filtered off and was washed with TBME (3×10ml). Drying under reduced pressure at 45°C. Yield: 6.53 g (75%).


10

*Example 1.3**Synthesis of ethyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate*


15

To a suspension of 5,6-diamino-nicotinic acid ethyl ester (1 eq., 5.0 g) in cyclohexanone (50 ml) bromobutanone (1.4 equiv., 5.95 g) was added over 15 min. The dark brown mixture was heated to 100°C (inner temperature) and stirred 1.5 h at this temperature. The mixture was cooled to room temperature and the light brown solid was filtered off and was washed with TBME (20 ml). Drying under reduced pressure at 45°C. Yield: 5.06 g (65%).


20

*Example 1.4**Synthesis of isopropyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate*

5 To a suspension of 5,6-diamino-nicotinic acid isopropyl ester (1 eq., 5.1 g) in cyclohexanone (50 ml) bromobutanone (1.2 equiv., 3.4 ml) was added over 10 min. The dark brown mixture was heated to 100°C (inner temperature) and stirred 1.5h at this temperature. The suspension was cooled to room temperature and the pale yellow solid
10 was filtered off and was washed with TBME (3x10ml). Drying under reduced pressure at 45°C. Yield: 6.0 g (74%).

*Example 1.5**Synthesis of 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide*


15 5,6-Diamino-nicotinamide (50 g, 0.313 mol (assay: 95.4%), 1.0 equiv.) was suspended in cyclohexanone (250 mL). The suspension was heated to 100°C. The filtrate
20 (bromobutanone in cyclohexanone) was added at 100°C over 1 h 10 min. Heating was continued for 3 h and the heating source was thereafter removed. The reaction mixture was allowed to cool to 20°C and stirred at this temperature for another 2 h. The solid was filtered off, washed carefully with TBME (2 x 330 mL) and dried to yield 70.3 g of title compound. Yield: 70%.

*Example 1.6**Synthesis of 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide*

5

NaBr (27.0 g; 0.259 mol; 1.33 equiv) was suspended in cyclohexanone (220 mL) and 3-chloro-2-butanone (25.7 mL; 0.242 mol; 1.24 equiv) was added in one portion. The mixture was heated to 80°C and stirred for 3 h. The mixture was cooled to 50°C, the white solid was filtered off and washed with cyclohexanone (60 mL). 5,6-Diamino-nicotinamide (30 g; 0.1946 mol; 1.0 equiv) was added to the filtrate and the mixture was heated to 100°C for 4 h, after which 98% conversion was determined by HPLC. The reaction mixture was cooled to 20°C, stirring was continued for 2h at 20°C. The solid was filtered off, washed with TBME (220 mL) and dried to yield 46.6 g of the title compound. Yield: 73%.

15

*Example 1.7**Synthesis of 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide*


20

5,6-Diamino-nicotinamide (30.0 g; 0.183 mol; 1.0 equiv) was suspended in cyclohexanone (280 mL). 3-Bromo-2-butanone (24 mL; 0.22 mol; 1.2 equiv) was added and the mixture was heated for 4 h to 100°C. The reaction mixture was cooled to 20°C and allowed to stir

for another 2 h. The solid was filtered off, washed with TBME (200 mL) and dried to yield 48.4 g of the title compound. Yield: 78%.

Example 1.8

5 *Synthesis of methyl 2,3-dimethyl-8-(2,6-dimethylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate*




10 Methyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (0.8 g, 3.6 mmol), 2,6-dimethylbenzylchloride (0.57 g, 3.7 mmol), sodium carbonate (1.0 g, 9.4 mmol) and a catalytic amount of potassium iodide were added to acetonitrile (10 ml) and were refluxed for 20 h. Following filtration, the salts were washed with methylene chloride and the solvents were evaporated under reduced pressure. The residue was purified by column
15 chromatography on silica gel using methylene chloride: ethyl acetate (75:25) as eluent. The yellow residue was treated with hexane to give 0.23 g (19%) of the title product.

Example 1.9

20 *Synthesis of ethyl 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate*

15




Ethyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (0.7 g, 3.0 mmol), 2-ethyl-6-methylbenzylchloride (0.5 g, 3.0 mmol), sodium carbonate (0.64 g, 6.0 mmol) and a catalytic amount of potassium iodide were added to acetone (50 ml) and were refluxed for 20 h. Following filtration, the acetone was evaporated under reduced pressure to give an oil. The oily product was purified by column chromatography on silica gel using diethyl ether : petroleum ether (1:1) as eluent to give 0.12 g (9%) of the title product. ¹H-NMR (500 MHz, CDCl₃): δ 1.25 (t, 3H), 1.5 (t, 3H), 2.35 (s, 3H), 2.42 (s, 3H), 2.44 (s, 3H), 2.75 (q, 2H), 4.45-4.5 (m, 4H), 4.9 (bs, 1H), 6.8 (s, 1H), 7.05-7.2 (m, 3H), 8.1 (s, 1H)

Example 1.10

Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-N-propyl-imidazo[1,2-a]pyridine-6-carboxamide

15




Ethyl 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylate (0.12 g, 0.33 mmol), propylamine (1.0 g, 17 mmol) and a catalytic amount of sodium cyanide were refluxed in methanol (20 ml) for 24 h. An additional amount of propylamine (1.0 g, 17 mmol) was added and the reaction mixture was refluxed for 24 h.

5 The solvent was evaporated under reduced pressure and the residue was purified by column chromatography on silica gel using diethyl ether as eluent. Crystallization from diethyl ether gave 0.053 g (42%) of the title compound. ¹H-NMR (300 MHz, CDCl₃): δ 1.0 (t, 3H), 1.2 (t, 3H), 1.65-1.75 (m, 2H), 2.3 (s, 3H), 2.35 (s, 3H), 2.38 (s, 3H), 2.7 (q, 2H), 3.4-3.5 (m, 2H), 4.35 (d, 2H), 4.9 (bs, 1H), 6.2 (bs, 1H), 6.35 (s, 1H), 7.0-7.2 (m, 4H),
10 7.85 (s, 1H).

Example 1.11

Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide




8-Amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide (3.3 g, 16.2 mmol), 2-ethyl-6-methylbenzylchloride (2.73 g, 16.2 mmol), potassium carbonate (8.0 g, 58 mmol) and
20 potassium iodide (1.1 g, 6.6 mmol) were added to acetone (150 ml) and refluxed for 20 h. An additional amount of 2-ethyl-6-methylbenzylchloride (1.0 g, 5.9 mmol) was added and the reaction mixture was refluxed for 7 h. Methylene chloride (60 ml) and methanol (30 ml) were added. The reaction mixture was filtered and the solvents were evaporated under reduced pressure. The residue was purified by column chromatography on silica gel using
25 methylene chloride: methanol (100:7) as eluent. Crystallization from ethyl acetate gave 2.8

g (50%) of the title compound. $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 1.2 (t, 3H), 2.34 (s, 3H), 2.36 (s, 3H), 2.38 (s, 3H), 2.7 (q, 2H), 4.4 (d, 2H), 4.9 (bs, 1H), 6.0 (bs, 2H), 6.45 (s, 1H), 7.0-7.2 (m, 3H), 7.9, (s, 1H).

5 *Example 1.12*

Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid




10

2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxamide mesylate (11.0 g, 0.025 mol) and sodium hydroxide (7.0 g, 0.17 mol) were solved in ethanol (95 %) (120 ml) and was refluxed for 20 h. The solvent was evaporated under reduced pressure and to the residue was added water (150 ml). The pH was adjusted to 5
15 by addition of conc. HCl and acetic acid and the solid that precipitated was isolated by filtration, washed with water and acetone, and dried to give 7.6 g (88 %) of the title compound. $^1\text{H-NMR}$ (500 MHz, DMSO-d_6): δ 1.15 (t, 3H), 2.26 (s, 3H), 2.34 (s, 3H), 2.39 (s, 3H), 2.69 (q, 2H), 4.38 (d, 2H), 5.2 (bs, 1H), 6.73 (s, 1H), 7.07-7.2 (m, 3H), 8.12 (s, 1H)

20 *Example 1.13*

Synthesis of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-6-(morpholinocarbonyl)-imidazo[1,2-a]pyridine


18



2,3-Dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid (0.15 g, 0.44 mmol) and o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium
 5 tetrafluoroborate (TBTU) (0.14 g, 0.44 mmol) were added to methylene chloride (10 ml). Morpholine (0.12 g, 1.4 mmol) was added and the reaction mixture was stirred at ambient temperature for 1.5 h. The reaction mixture was added to a column with silica gel and purification by chromatography using ethyl acetate : methylene chloride (1:1) as eluent gave 0.12 g (66%) of the desired product. ¹H-NMR (300 MHz, CDCl₃): δ 1.2 (t, 3H), 2.32
 10 (s, 3H), 2.35 (s, 3H), 2.37 (s, 3H), 2.7 (q, 2H), 3.7 (s, 8H), 4.35 (d, 2H), 4.95 (bs, 1H), 6.15 (s, 1H), 7.0-7.2 (m, 3H), 7.4 (s, 1H)

Example 1.14

Synthesis of (2-ethyl-6-methylbenzylamino)-N(2-(2-hydroxyethoxy)ethyl)-2,3-
 15 *dimethylimidazo[1,2-a]pyridine-6-carboxamide*




2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo[1,2-a]pyridine-6-carboxylic acid
 20 (0.3 g, 0.88 mmol) and o-Benzotriazol-1-yl-N,N,N',N'-Tetramethyluronium tetrafluoroborate (TBTU) (0.29 g, 0.90 mmol) were added to methylene chloride (10 ml). 2-(2-aminoethoxy)ethanol (0.2 g, 1.9 mmol) was added and the reaction mixture was stirred at ambient temperature for 2 h. The solvent was evaporated under reduced pressure and the


residue was purified by column chromatography on silica gel using methylene chloride:methanol (9:1) as eluent. Crystallization from diethyl ether gave 0.24 g (80%) of the desired product. ¹H-NMR (500 MHz, CDCl₃): δ 1.25 (t, 3H), 2.25 (s, 3H), 2.3 (s, 3H), 2.35 (s, 3H), 2.75 (q, 2H), 3.4-3.45 (m, 2H), 3.55-3.7 (m, 6H), 4.35 (d, 2H), 5.05 (t, 1H), 6.45 (s, 1H), 7.0-7.2 (m, 4H), 7.5 (s, 1H)

Example 1.15

Synthesis of isopropyl 8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate



Isopropyl 8-amino-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (9.85 kg, 1.0 equiv., 29.71 mol) was suspended in isopropanol (59 L); NaI (0.6 equiv., 2.68 kg, 17.88 mol) and K₂CO₃ (2.5 equiv, 10.29 kg, 74.48 mol) were added and the mixture was heated to about 70°C. 2,6-Dimethylbenzyl chloride (1.1 equiv, 5.22 kg, 32.77 mol) was dissolved in isopropanol (~60 L) and this solution was added to the reaction mixture. After the addition was complete, the temperature was kept at 60°C for additional 1.5 hours. Additional K₂CO₃ was added (9.15 kg) and the resulting suspension was stirred for further 2h at 60°C. Additional 2,6-dimethylbenzyl chloride (2.76 kg) in isopropanol (22L) was added slowly at an temperature of 60°C; after the addition the reaction mixture was stirred for further 4 hours at this temperature. The suspension was diluted with water (124L), cooled, stirred and filtered. The filtercake was washed with water and then with cold isopropanol, dried under reduced pressure at 40°C to give 11.37 kg wet material, yield: 90%.

*Example 1.16**Synthesis of 8-[(2,6-dimethylbenzyl)amino]-N-(2-hydroxyethyl)-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxamide*

5

A reactor was charged with isopropyl 8-[(2,6-dimethylbenzyl)amino]-2,3-dimethylimidazo[1,2-a]pyridine-6-carboxylate (11.30 kg, 1 equiv., 27.02 mol) and THF (45 L), ethanolamine (18.97 kg, 11 equiv., 309.2 mol) was added at about 20°C. The suspension was heated to about 100°C. Some solvent was distilled off and then THF (35 L) was added and the distillation was continued. The procedure of adding THF and distilling it off was repeated until complete conversion. To the suspension ethanol (140L) was added and the suspension was heated to reflux. To obtain a clear solution additional ethanol (13L) was added. The hot solution was filtered and then cooled. The white solid was filtered off, washed with ethanol and dried to yield the product as a white powder. (8271 g).

15

2. PREPARATION OF STARTING MATERIALS*Example 2.1**Synthesis of 6-amino-5-nitro-nicotinamide*

100 g of 6-hydroxy-5-nitro-nicotinic acid (0.54 mol; HPLC > 98% area) was suspended in toluene (750 mL). DMF (1 mL, 0.013 mol, 0.024 equiv.) was added and the mixture was heated to 110 °C (inner temperature). Thionylchloride (99 mL, 2.5 equiv.) was added over 120 min. Heating was continued for 4h at 110°C. The reaction mixture was concentrated to half the volume (400 mL of solvent were distilled off), and toluene (400 mL) was added.

20

This procedure was repeated once again (410 mL of toluene were distilled off and fresh toluene (410 mL) was added again). The solution was then cooled to 20°C and slowly added to aqueous ammonia (25%, 440 mL, 12 equiv.) over 40 min. Precipitation started immediately. During the addition the temperature was maintained below 15°C. After the addition had been completed the reaction mixture was allowed to warm up to room temperature and stirring was continued for 16h. The solid was filtered off, washed with water (500 mL), ethanol (250 mL), TBME (250 mL) and dried (50-10 mbar, 40°C bath temperature, 16 h) to yield 91.3 g of the title compound (0.501 mol, 87%).

10 *Example 2.2*

Synthesis of 5,6-diamino-nicotinamide

44.5 g of 6-amino-5-nitro-nicotinamide (0.24 mol; HPLC: 93% area) were suspended in methanol/water 1:1 (500 mL), 5.0 g of catalyst [Pd(4%)-Ru(1%)/C paste (62% H₂O type: 485; Johnson Matthey); type: 485; Johnson Matthey] was added. Hydrogenation was carried out at 5 bar and 30°C for 5h. After completion the catalyst was filtered off and washed with methanol/water 1/1 (50 mL). 480 mL of the solvent was distilled off. The resulting suspension was cooled to 20°C and filtered off. The solid was washed with methanol (20 mL) and TBME (30 mL). After drying (200-10 mbar; 40°C bath temperature, 16 h) 27.3 g of the title compound (0.18 mol, 73%) were obtained.

20

Example 2.3

Synthesis of 5,6-diamino-nicotinamide

42.3 g of 6-amino-5-nitro-nicotinamide (0.23 mol, HPLC: 93% area) was suspended in methanol/water 1:1 (500 mL). 5.2g of catalyst [Pd(5%)/C (57.8% H₂O); type: 39, Johnson Matthey] was added. Hydrogenation was carried out at 5 bar and 30°C for 4h. After completion the catalyst was filtered off and washed with methanol/water 1/1 (100 mL). 550 mL of the solvent was distilled off. The resulting suspension was cooled to 20°C and filtered off. The solid was washed with methanol (20 mL) and TBME (30 mL). After drying (200-10 mbar; 40°C bath temperature, 16 h) 28.5 g of the title compound (0.18 mol, 78%) was obtained.

30

CLAIMS

1. A process for preparing a substituted imidazopyridine compound of formula (1)




(1)

5

wherein R^1 is $\text{C}_1\text{-C}_6$ alkoxy or NH_2 ,

comprising the step of reacting a compound of the formula (2)



(2)

10 with a 3-halo-2-butanone compound in cyclohexanone.

2. A process according to claim 1, wherein the 3-halo-2-butanone compound is 3-bromo-2-butanone or 3-chloro-2-butanone.

15 3. A process according to claim 1 or 2, wherein the amount of the 3-halo-2-butanone compound is 1.1 to 5 molar equivalents.

4. A process according to claim 1, wherein the reaction temperature is 80°C to 100°C .


20 5. A process according to claim 1, wherein cyclohexanone is diluted with an inert solvent.

6. A process according to claim 1, wherein R^1 is $\text{C}_1\text{-C}_6$ alkoxy.

23

7. A process according to claim 1, wherein R^1 is NH_2 .

8. A process according to claim 1, characterized in that compound (2) is prepared by a
5 process comprising the step of hydrogenating a compound of formula (4)




(4)

in an aqueous alcoholic solution using a catalyst.

9. A process according to claim 8, wherein the catalyst is a Pd-Ru/C paste.

10. A process according to any of claim 8 or 9, characterized in that compound (4) is
prepared by a process comprising the step of reacting a compound of formula (3)



(3)

with thionyl chloride to give the corresponding chloride compound, which is thereafter
treated with ammonia.

20

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER: _____**

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01897

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 471/04, C07D 213/803, C07D 213/82
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI DATA, PAJ, CHEM. ABS DATA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9955706 A1 (ASTRA AKTIEBOLAG), 4 November 1999 (04.11.99), page 7 - page 12; page 39 - page 45, claims 8, 9 --	1-10
X	EP 0308917 A2 (FUJISAWA PHARMACEUTICAL CO., LTD), 29 March 1989 (29.03.89), page 8 --	1-7
A	EP 0033094 A1 (SCHERING CORPORATION), 5 August 1981 (05.08.81), page 8, claim 10 -- -----	1-10

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

4 January 2002

17-01-2002

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Gerd Strandell/EÖ
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT
Information on patent family members

06/11/01

International application No.

PCT/SE 01/01897

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9955706	A1	04/11/99	AU	727349 B	14/12/00
				AU	4300699 A	16/11/99
				AU	4300799 A	16/11/99
				AU	9098998 A	22/03/99
				BR	9909995 A	26/12/00
				BR	9909996 A	26/12/00
				CN	1306533 T	01/08/01
				CN	1307577 T	08/08/01
				EP	1011653 A	28/06/00
				EP	1073656 A	07/02/01
				EP	1073657 A	07/02/01
				JP	2001514215 T	11/09/01
				NO	20001087 A	02/03/00
				NO	20005450 A	22/12/00
				NO	20005451 A	27/12/00
				PL	338982 A	04/12/00
				SE	9801526 D	00/00/00
				US	6245818 B	12/06/01
				WO	9955705 A	04/11/99
EP	0308917	A2	29/03/89	AU	2278388 A	06/04/89
				CN	1033628 A	05/07/89
				DK	532088 A	25/03/89
				FI	884318 A	25/03/89
				GB	8722488 D	00/00/00
				HU	48245 A	29/05/89
				HU	201934 B	28/01/91
				IL	87809 D	00/00/00
				JP	1151579 A	14/06/89
				NO	884231 A	28/03/89
				US	4920129 A	24/04/90
				ZA	8806831 A	30/05/89

INTERNATIONAL SEARCH REPORT

Information on patent family members

06/11/01

International application No.

PCT/SE 01/01897

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0033094 A1	05/08/81	SE 0033094 T3	
		AU 540840 B	06/12/84
		AU 6633781 A	30/07/81
		CA 1167845 A	22/05/84
		DE 3166531 D	00/00/00
		DK 25081 A	24/07/81
		ES 498643 A	16/11/82
		FI 810147 A	24/07/81
		GR 72960 A	19/01/84
		HK 94187 A	18/12/87
		HU 185857 B	28/04/85
		IE 50682 B	11/06/86
		IL 61939 A	31/01/86
		JP 56113782 A	07/09/81
		KR 8500240 B	12/03/85
		MY 76087 A	31/12/87
		NO 157781 B,C	08/02/88
		NO 810198 A	24/07/81
		NZ 196071 A	31/05/84
		OA 6727 A	30/06/82
		PT 72370 A,B	01/02/81
		SG 70887 G	04/03/88
		ZA 8100219 A	27/01/82